Details of the Drug
General Information of Drug (ID: DMZQXLS)
Drug Name |
N-Trimethyllysine
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
N-TRIMETHYLLYSINE; Trimethyllysine; epsilon-Trimethyllysine; N(epsilon)-Trimethyllysine; epsilon-Trimethyl-L-lysine; epsilon-N-Trimethyl-L-lysine; UNII-3YGF0495O2; CHEBI:17311; 3YGF0495O2; (S)-5-Amino-5-carboxy-N,N,N-trimethyl-1-pentanaminium; 19253-88-4; 1-Pentanaminium, 5-amino-5-carboxy-N,N,N-trimethyl-, (S)-; M3L; (S)-2-amino-6-(trimethylammonio)hexanoic acid; N-N-N-Trimethyllysine; N-epsilon-trimethyllysine; epsilon-N-Trimethyllysine; AC1L98PV; SCHEMBL181192; CHEMBL1234168; MXNRLFUSFKVQSK-QMMMGPOBSA-O; ZINC1529747
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 1 | Molecular Weight (mw) | 189.28 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | -2.1 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 6 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 2 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 3 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||||||||